Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.

Insulin clearance was increased with both doses of canagliflozin compared with placebo, although the increase observed with the 100 mg dose did not reach statistical significance ( p = 0.07) (ESM Table 2 ); the increase in insulin clearance observed with the 300 mg dose compared with placebo was approximately 24% ( p < 0.0001).

also in 111,027 other papers